DFM Platform
DFM Funding Monitor

A multiplexed biomimetic imaging platform for assessing single cell plasticity (Plastomics) and scoring of tumour malignancybroad

PLAST_CELL · Horizon Europe grant · 2022-05-01–2026-10-31

EC contribution

€2,982,792

Total cost

€2,982,792

Beneficiaries

6
About the data

Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2021-PATHFINDEROPEN-01 · scheme HORIZON-EIC · topic HORIZON-EIC-2021-PATHFINDEROPEN-01-01. CORDIS record →

Objective

Metastasis is the major cause of death in cancer patients due to cancer cell dissemination to distant organs. Cell plasticity is a core characteristic of metastatic cells and confers cellular adaptation capabilities to variable mechano-chemical tissue microenvironments. However, to date, specific quantitative measures of cancer cell plasticity associated with tumour aggressiveness and therapy resistance have remained difficult to establish. A major limitation is the availability of highthroughput multiplexed assays that can capture phenotypic heterogeneity and morphodynamic plasticity at the single cell level in standardized 3D culture conditions reflecting in vivo tissue microenvironments. The PLAST_CELL interdisciplinary consortium will pioneer the development of a microfluidics-based imaging platform to categorize and score cancer cell plasticity within diverse physiologically relevant 3D biomimetic culture conditions. The platform will enable to perform single cell multi-scale morphometric and molecular live cell data collection (PLAST_DATA) with minimal sample size (<10k cells). Data will be generated based on single molecule-sensitivity marker detection and cellular/subcellular morphodynamic feature recognition via minimal-invasive long-term super-resolution microscopy and parallel morphodynamic imaging of cellular behaviour. Computational integration of PLAST_DATA using preclinical models and patient samples will enable to develop a quantitative classification of tumour cell plasticity and predictive scoring of cancer aggressiveness, metastasis and drug resistance (PLAST_SCORE). The ability to assess cell plasticity based on cellular behaviours is beyond current clinical parameters and will strongly impact diagnosis, prognosis and treatments. The PLAST_CELL platform will be a technology breakthrough to establish new quantitative standards to evaluate cell plasticity and mechanisms of tumour malignancy for a new era of basic research and personalized medicine.

Beneficiaries (6)

OrganisationCountryRoleEC contributionSME
FUNDACIO CENTRE DE REGULACIO GENOMICA ES coordinator €1,063,091
FUNDACIO INSTITUT HOSPITAL DEL MAR D INVESTIGACIONS MEDIQUES ES participant €669,375
CHERRY BIOTECH FR participant €472,438 Yes
FUNDACIO INSTITUT DE CIENCIES FOTONIQUES ES participant €375,250
EUROPEAN MOLECULAR BIOLOGY LABORATORY DE participant €358,888
UNIVERSITAET INNSBRUCK AT participant €43,750

Get the EU Defence Funding Calendar — free

The full calendar of open EU defence and dual-use funding calls, sorted by deadline, updated nightly. Delivered with DFM Analysis, our weekly briefing on who is funding what in European defence.

We store your email to send the calendar and the weekly DFM Analysis briefing. Nothing else. Unsubscribe anytime.

Or browse all open defence & dual-use calls on the funding calendar →

Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; the paid Annual Professional subscription is handled on DFM Analysis.

DFM Analysis, our free weekly newsletter, tracks the EU defence-funding programmes, calls and decisions behind this page. Subscribe free →